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from published studies conducted in the UK and included
direct medical and indirect costs. Resource unit costs
were obtained from published sources. Vaccination pro-
gram costs were included. Future costs were discounted
5%. RESULTS: The incremental cost per year of life
gained in the under one year old group was £4,280 with-
out discounting the benefit and £6,357 with discounting.
The incremental cost per life year gained in the cohort
aged 1–4 years was £1,060 without discounting the bene-
fit and £1,557 with discounting the years of life gained.
Both age group ratios increase as the costs of managing
acute and long-term sequelae are decreased. Assuming a
higher proportion of meningococcal infections are sero-
type C (40%) results in ratios of £3,146 and £470 for the
younger and older groups, respectively. CONCLU-
SIONS: The cost-effectiveness ratios for vaccinating chil-
dren under age 1 and between ages 1 and 4 fall within the
generally acceptable range of costs for adopting new
technology.
CEB3
COST-EFFECTIVENESS OF PREVENTION OF 
CORONARY HEART DISEASE (CHD) WITH 
SIMVASTATIN IN POLAND
Kuzniar J, Orlewska E, Hermanowski T, Romanczuk W, 
Splawinski J
Institute of Drugs, Warsaw, Poland
Cost-effectiveness of secondary prevention of CHD in the
Western World with simvastatin (S) is well established.
OBJECTIVE: Cost-effective evaluation of secondary pre-
vention of CHD with simvastatin in the Polish setting
with the health care system in a transition period.
METHOD: It was assumed that the effects of S in Polish
patients would be the same as those of Scandinavian Sim-
vastatin Survival Study. Direct medical costs were ob-
tained from Polish sources. ICER was calculated dividing
net costs by years of life gained during 5.4 years of treat-
ment with S projected over an average life expectancy of
10 years. One-way and multi-way sensitivity analyses
were performed. Frequency of hospitalizations, costs of
hospitalizations, and life-years saved were the variables
used in Monte Carlo analysis. RESULTS: Net cost/pa-
tient (discounted at 5%) was $2478.5; cost per life-years
saved (LYS) was $10,326.8 (mean ICER from Monte
Carlo analysis was $10,243.9). ICER value was highly
sensitive to the price of S and relatively insensitive to the
value of savings (including saving of PTCA, CABG, myo-
cardial infarction, and hospitalisations). The latter, in
Polish settings, amounted to only 8.2% of drug cost (in
Sweden 30%). The cost per LYS is higher than the cost
of 1 year of hemodialysis and about 3 times higher than
the GNP per capita ($3527.6) in Poland. CONCLU-
SIONS: Results indicate that secondary prevention of
CHD in patients with mild hypercholesterolemia with S
in Poland is hardly cost-effective due to the low value of
savings. The value of medical services in Poland is proba-
bly underestimated.
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THE COST-EFFECTIVENESS OF FIXED-DOSE 
COMBINATION OF DICLOFENAC AND 
MISOPROSTOL IN PREVENTION OF NSAID-
INDUCED ULCERS IN RHEUMATOID ARTHRITIS 
PATIENTS IN POLAND
Orlewska E
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OBJECTIVES: Cost-effectiveness estimation of treatment
with a fixed-dose combination of diclofenac and miso-
prostol (FDC D-M) 50 mg/200 mcg bid compared with
diclofenac (D) 50 mg bid in prevention of NSAID-induced
ulcers in rheumatoid arthritis (RA) patients in Poland.
METHODS: A decision model for FDC D-M in the Pol-
ish health care context was developed, based on epidemi-
ological and clinical data from the literature and local
data on health care resource utilization and unit cost.
Only direct medical costs are analyzed. The perspective
of health care payers (sickness funds  patients) is taken.
The time horizon is 3 months, but consequences of a
longer time horizon are discussed. Cost-effectiveness was
calculated for the treatment of all RA patients and risk
groups only. Effectiveness was expressed in life-years
saved. The cost-effectiveness threshold, calculated on basis
of 1-year of haemodialysis treatment cost ($15,600 US)
or national GDP per head at PPP ($6300 US), was sug-
gested to asses whether the FDC D-M therapy should be
adopted. RESULTS: Analysis showed that FDC D-M treat-
ment in RA patients gives additional life years for extra
cost. In all RA patients (aged 65) 1 LYG costs $33,700
US. Cost per LYG was below the suggested cost-effective-
ness threshold only in patients at high risk (history of
peptic ulcer disease or GI bleeding, disability—mHAQ
1.5, concomitant antacid therapy). One-way sensitivity
analysis showed that outcomes are sensitive to changes
in: price differences between FDC-D-M and D, percent
ulcers, and the efficacy of misoprostol. CONCLUSION:
FDC D-M treatment in Poland is cost-effective only in
RA patients at high risk for NSAID-induced ulcers.
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Cisapride, an oral GI prokinetic agent, was reported to
cause serious cardiac arrhythmia in patients who received
imidazole antifungals, macrolide antibiotics, or protease
inhibitors. Several label changes and dear Dr. letters were
sent to prescribers in February and October 1995, and
June 1998. OBJECTIVE: To quantify the effectiveness of
label changes and dear Dr. letters on patient medication
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with cisapride and contraindicated drugs. METHODS:
Using a managed care database, a total of 38,757 pa-
tients with cisapride prescriptions from July 1993 to De-
cember 1998 were selected. The outcomes measured are
proportions of overlapping cisapride prescriptions and
coexposed therapy days dispensed with contraindicated
drugs per month/year. Poisson regression analyses were
conducted to evaluate changes in the proportion of over-
lapping contraindicated prescriptions after each interven-
tion. RESULTS: About 3.7% cisapride prescriptions
were overlapped with contraindicated drugs. Of those,
51% were prescribed by the same physician; 17% were
dispensed on the same day; and 97% were dispensed by
the same pharmacy. After controlling for seasonal varia-
tion, both interventions in October 1995 and June 1998
significantly reduced the proportion of overlapping con-
traindicated prescriptions. We found a 15% reduction (P 
0.0357) following the October 1995 intervention and a
subsequent 30% reduction (P  0.0002) following the
June 1998 intervention. No significant decline was found
for the February 1995 intervention. The proportion of
overlapping with antibiotics shows a seasonal pattern
with peaks in the winter. Young and middle-aged pa-
tients were more likely to get overlapping contraindicated
prescriptions than children and elderly patients (P 
0.0001). CONCLUSIONS: Decreases in the proportions
of overlapping medications were observed after product
label changes accompanied by dear Dr. letters and associ-
ated information.
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Overactive bladder (OAB) characterized by symptoms of
urinary incontinence, frequency, or urgency is a highly
prevalent disorder that impacts the lives of millions of
people in the US. OBJECTIVES: This study examines
healthcare cost consequences of OAB among non-elderly
adults, and factors that give rise to higher costs among
patients with OAB. METHODS: Data were analyzed
from patients 18 to 64 years of age who filed one or more
insurance claims between January 1994 and December
1995. Two patient cohorts were identified: 146,312 who
received no OAB services and 2,385 who received OAB
services. Multiple regression was used to breakdown cost
differences between cohorts into 3 components: costs for
OAB services, costs imposed by OAB on treating other
conditions, and cost of treating additional medical prob-
lems in OAB patients. Pearson chi-square tests were used
to assess differences between cohorts. RESULTS: OAB
patients were primarily women over 40 with significantly
higher relative risk of urogenital problems and depres-
sion than non-OAB patients (P  0.001). OAB patients
were also significantly more likely to be hospitalized and
to stay longer (P  0.001). Average annual claims for
OAB patients were $5018 vs $1767 for non-OAB pa-
tients. This difference was due to a greater prevalence of
problems in OAB patients ($2456), receipt of OAB ser-
vices ($161), and additional costs of non-OAB care
($634). CONCLUSIONS: Insurance claims for adult pa-
tients with OAB are higher than for non-OAB patients.
The impact of OAB on non-OAB diseases may be a sub-
stantial cost driver. The use of effective and safe agents to
treat OAB should have a significant impact on reducing
the total costs of treating these patients.
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Traditionally in many managed care program, govern-
mental or private, coverage for smoking cessation phar-
macotherapy has been excluded. Beginning in January
1999, Kansas Medicaid allowed coverage for nicotine
transdermal systems (NTS), bupropion, and combination
therapy for smoking cessation. A review of the success of
coverage of these products, and the impact on the Medic-
aid program was conducted after six months. OBJEC-
TIVES: The study purpose was to determine the quit
rates associated with covered smoking cessation pharma-
cotherapy. METHODS: Clients prescribed these thera-
pies over the first six months of drug coverage were iden-
tified from drug utilization review (DUR) profiles and
contacted via a mailed survey to assess self-reported suc-
cess rates. Statistical analyses included use of analysis of
variance (ANOVA) with follow-up tests, and chi-square
comparisons. RESULTS: A total of 25% of the 700 re-
spondents, with an average age of 49 years and who
smoked an average of 33.6 years, achieved smoking ces-
sation success. Successful quit rates were higher with
NTS (29.4%), than for bupropion (22.7%), or the com-
bination of NTS and bupropion (13.9%). Differences in
these success rates between the three therapeutic options
were significant at level of P  0.001. CONCLUSIONS:
Research analyzing the clinical and economic outcomes
of coverage of smoking cessation therapies resulted in a
policy change allowing the coverage of smoking cessation
products in the Kansas Medicaid program. The results of
this study indicate that success rates can be expected
from coverage of such products. Careful selection of the
products used may be required based upon the results of
this study.
